Breaking: FDA grants accelerated approval of Leqembi (lecanemab) for treatment of the early stages of Alzheimer’s with confirmation of amyloid beta. This is a milestone achievement for those eligible for treatment, their families & the research community. https://t.co/HuGINgcyUh

— Alzheimer's Association (@alzassociation) January 6, 2023